A new hypothesis from a leading NMDA receptor researcher suggests ketamine may work by weakening active brain circuits. Here is what that could mean for clinical practice.

KSU alumnus Dr. Ray Rivas went from cash-pay IV ketamine only to nearly 90% insurance-based -- after adding Spravato. Here's his honest account of what worked, what didn't, and what he wishes he'd known sooner.